(Bloomberg) — Illumina Inc. and Pacific Biosciences of California Inc. called off their planned $1.2 billion deal after U.S. antitrust enforcers last month moved to block the merger of the DNA-sequencing companies.The transaction had been on hold for more than a year after being announced in November 2018. But antitrust authorities in the U.S. and the U.K. had pushed back against it, and the U.S. Federal Trade Commission filed a complaint to block it last month.“Considering the lengthy regulatory approval process the transaction has already been subject to and continued uncertainty of the ultimate outcome, the parties decided that terminating …read more
Source:: Yahoo Finance
